Approach to Selecting Treatment for Myelofibrosis in 2024

GRACE

A. Srisuwananukorn

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

Management of MF After Ruxolitinib Failure

Vanderbilt University Medical Center (VUMC)

A. Kishtagari

Overview of Recent Updates in MPNs and MDS

UChicago Medicine

S. Kosuri

Updates on Myeloproliferative Neoplasms Including CML

Winship Cancer Institute - Emory University

A. Hunter

Emerging Therapies in MF & PV: Insights From Recent Clinical Trials

Yale Cancer Center

J. Bewersdorf

State of the Art and Next Questions: MPN

SOHO Highlights: State of the Art and Next Questions

J. Mascarenhas

2024 Updates in Myeloproliferative Neoplasms

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Hexner

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

Current Treatment Landscape of JAK Inhibitors in MF

Moffitt Cancer Center

A. Kuykendall

Correlation of Bone Marrow Fibrosis Changes and Efficacy During Mome…

Mary Frances McMullin

Quality of Life in Myelofibrosis Patients Treated With Momelotinib

Mary Frances McMullin

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Indy Hematology Review

R. Rampal

QoL in Pts With MF: Highlighting the Need for New Agents

Jeanne Palmer

Management of MPNs for the Community Oncologist

Fred Hutchinson Cancer Center

H. Deeg

Experts Discuss the Latest Data in Myeloid Diseases

Moffitt Cancer Center

A. Kuykendall, R. Komrokji, O. Chan, D. Sallman